Investigation of the impact of clonal hematopoiesis on COVID-19 disease severity. (A) Proportion of patients carrying at least 1 driver CH mutation in all 3 COVID-19 patient cohorts combined. (B) Distribution of CH driver mutations by gene in nonhospitalized, hospitalized, and ICU patients. (C) Proportion of patients carrying at least 1 driver mutation in nonhospitalized, hospitalized, and ICU COVID-19 patients. P value was calculated using χ² test. (D) Proportion of patients at least 1 CH driver mutation in nonhospitalized, hospitalized, and ICU COVID-19 patients across different age groups. (E) Number of CH driver mutations per patient in nonhospitalized, hospitalized, and ICU COVID-19 patients. (F) VAF distribution of CH driver mutations in nonhospitalized, hospitalized, and ICU COVID-19 patients. P value is calculated using 1-way analysis of variance. (F) Driver CH mutation gene distribution in nonhospitalized, hospitalized, and ICU COVID-19 patients. (G) VAF of driver CH mutations on day 1 and day 9 of ICU admission in individual patients. P value is calculated using t test. (H) Multivariate proportional odds model shows that the presence of CH, number of mutations per patient, VAF, CH mutation of ≥ 5% VAF, CH mutation of ≥ 10% VAF, DNMT3A mutation, and TET2 mutation are not associated with an increased risk of COVID-19 hospitalization and ICU admission. Age, sex, ethnicity, diabetes, chronic obstructive pulmonary disease/asthma, CVD, cancer/neoplasm, immunodeficiency, and smoking status were adjusted for.